Bayer AG's consumer health business has launched its Precision Health business unit focused on digital and digital-supported consumer health products.
Bayer Focuses On Medical Technology For Consumers With Precision Health Unit
German pharma giant says division will help people take control of their own health care with digital products.

More from Digital Technologies
Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”
AI prowess “will not be a competitive advantage long-term. It's going to be table stakes. But there are people who are going to get there sooner and they will have an advantage for a while,” says C&D CEO Matthew Farrell. P&G’s investment in AI, meanwhile, produced its “Great Idea Generator proprietary platform.”
Electronic product information should be “fully operational” within four years after the entry into force of the revised EU pharma legislation and should precede the phasing out of paper leaflets, proposes the Inter-Association Taskforce (IATF) on ePI. Once the new system is up and running, ePI should be implemented across the EU in a harmonized way, with all EU member states adopting the same standard, it says.
Developed using Datair's Ambee climate data technology, Opella’s Pollen Passport presents users with an easy to use and interactive online visualization of air quality at holiday destinations across the world.
More from HBW Insight
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. “If we reauthorize it, will it continue?” Texas representative Lizzie Fletcher asks of OMUFA.
Single-use packaging producers subject to Oregon state’s Extended Producer Responsibility law that didn’t meet the 31 March deadline to report their packaging materials are given a grace period to report until 30 April, says Circular Action Alliance, the organization carrying out the EPR program.
Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.